Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
13 févr. 2024 08h30 HE
|
Lantheus Holdings, Inc.
Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ:...
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
08 févr. 2024 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus Announces CEO Succession Plan
23 janv. 2024 07h45 HE
|
Lantheus Holdings, Inc.
Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and...
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
11 janv. 2024 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling...
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
09 janv. 2024 08h00 HE
|
Lantheus Holdings, Inc.
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective...
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
09 janv. 2024 07h55 HE
|
Lantheus Holdings, Inc.
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023...
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
18 déc. 2023 07h30 HE
|
Lantheus Holdings, Inc.
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 ...
Lantheus to Present at the Jefferies London Healthcare Conference
08 nov. 2023 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Reports Third Quarter 2023 Financial Results
02 nov. 2023 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year periodGAAP net income of $132.0 million for the third quarter 2023, compared to...